Navigation Links
SEP Signs REGURIN(R) Deal
Date:6/18/2009

LONDON, June 18 /PRNewswire/ --

- Speciality Urology Company Gains Exclusive UK Distribution Rights

Speciality European Pharma Limited (SEP), the UK based, urology focused, specialty pharmaceutical company, is pleased to announce that it will obtain the exclusive distribution rights to Regurin(R) (trospium chloride) for the UK and Ireland, as of the 1st July 2009. Regurin, owned by Rottapharm-Madaus, is currently marketed under different brand names in European countries including Germany, Italy, Austria, Spain and Switzerland.

Regurin is licensed for use in men and women to treat the symptoms of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder (OAB). Urinary incontinence is an embarrassing problem estimated to affect over a third of women over 40[1]. Regurin is an anti-muscarinic, which reduces the contractions of the detrusor muscle in the bladder and increases bladder capacity.[2] It is well tolerated with a low incidence of the common anti-muscarinic side effect, dry mouth.[3],[4] Regurin also does not cross the blood-eye or blood-brain barrier[5],[6],[7] reducing the incidence of confusion in people taking this treatment.[8],[9],[10],[11]

"Trospium chloride is central to managing certain types of urinary incontinence and is one of the recommended options by the National Institute for Health and Clinical Excellence (NICE) for use in women with mixed urinary incontinence of OAB after generic oxybutynin," said Professor Linda Cardozo, Kings College Hospital, London. "It's side effect profile is particularly beneficial to patients."

Commenting on the deal, Geoff McMillan, Chief Executive Officer of SEP, said: "This agreement provides us with a well established and clinically superior product in the field of urology, an area that remains the focus of our company. This deal demonstrates our
'/>"/>

SOURCE Speciality European Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. SleepQuest Signs National Contract With Aetna
2. A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd.
3. Insmed CEO Resigns Due to Health Concerns
4. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
5. Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago
6. LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
7. Prometheus Research Signs 3-Year Contract With Simons Foundation to Expand HTSQL Informatics System for Autism Research
8. Assay Designs(TM), Inc. Announces Release of First Available Product for Multiplex Analysis of Heat Shock Proteins
9. Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry
10. ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicons Research and Diagnostic Products
11. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  AnaptysBio, Inc., a leader in the ... announced the advancement of its first-in-class anti-interleukin-36 ... The Company,s anti-IL-36R therapeutic antibody, called ANB019, ... psoriasis (GPP), an orphan systemic inflammatory disease ... owned within AnaptysBio,s proprietary antibody pipeline and ...
(Date:4/16/2015)... 16, 2015  EMD Serono today announced the ... Germany , appointed Alise Reicin ... Global Clinical Development.  Dr. Reicin brings extensive research ... Oncology and Immunology. She is an accomplished pharmaceutical ... a Vice President in various capacities across R&D ...
(Date:4/16/2015)... 16, 2015 Fairleigh Dickinson University ... Gulfo to become the Executive Director of the ... announced the kick-off of the Initiative for Patient ... Dr. Gulfo, under the Rothman Institute of Innovation ... and in collaboration with FDU’s School of Pharmacy’s ...
(Date:4/16/2015)... Modality Solutions, a company that delivers ... industries, is pleased to announce its President, Gary ... Cold Chain IQ - Temperature Control Logistics and ... Global Cold Chain Connections, is dedicated to sharing ... pharmaceutical and healthcare supply chains. , Cold ...
Breaking Biology Technology:AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a ... small molecule therapeutics for,the treatment of cancer, today ... JMP Securities Healthcare Focus Conference in Boston. ... p.m. (Eastern) on,Tuesday, November 13, 2007. There will ...
... ... treatment issues, SAN RAMON, Calif., Nov. 7 ... advisory group,designed to tackle head-on the increasingly complex ethical issues of,infertility medicine ... RSC,s ethics committee, believed to be the second of its kind among,infertility ...
... SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a biomaterials ... tissue repair and drug delivery,products, announced today that ... the Securities and Exchange Commission (SEC) that, if,declared ... sell, from time to,time, up to $20 million ...
Cached Biology Technology:Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference 2California IVF Experts Tap Ethics Committee for Guidance 2SyntheMed Files Universal Shelf Registration 2
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
(Date:3/31/2015)... 2015  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ... Software Defined Network Architecture (ET Software DNA® 2.0) platforms ... approximately $20.4 million for the year ended December 31, ... the year ended December 31, 2013. ... completed its multi-year transition away from its legacy landline ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... CORVALLIS, Ore. A new study by Oregon State ... often know what kinds of foods they should be eating, ... money for meals. Joan Gross and Nancy Rosenberger, both ... rural Oregonians living in poverty by conducting in-depth interviews with ...
... it is for pregnant women to eat good, nutritious food. ... children who are less likely to develop type 1 diabetes, ... at the University of Gothenburg, Sweden. The ... conducting a population study called ABIS (All Babies in Southeast ...
... Ala. An experimental drug cocktail that includes ... hope in developing a single agent to treat ... in the University of Alabama Birmingham (UAB) Division ... the triple combination of oseltamivir (Tamiflu), amantadine (Symmetrel) ...
Cached Biology News:Poor in rural Oregon face 'double binds' when getting food 2Poor in rural Oregon face 'double binds' when getting food 3Vegetables can protect unborn child against diabetes 2Triple-combo drug shows promise against antiviral-resistant H1N1, UAB researcher says 2
... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' overhang ... polymerase which exhibits very high activity in ... To ensure the quality of the enzyme, ...
... Recombinant DNA polymerase from Thermus aquaticus expressed ... contamination; 1 tube of 250 units enzyme/tube ... (Low DNA), is the same enzyme as ... through a proprietary separation process to ensure ...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
Taq DNA polymerase, 10,000U...
Biology Products: